Avomeen Announces New President
Avomeen Analytical Services announces that David W. Riggs, PE will take the role of president of the company.
Avomeen Analytical Services announced on April 7, 2015 that it would appoint David W. Riggs as president of the company. Riggs will join Avomeen with almost 30 years of experience in advanced analytical chemistry, product development, chemical engineering, and other roles within the industry.
“David brings excellent credentials into our growing laboratory; his dedication to building successful relationships with clients through long-term mutually beneficial business partnerships is to be admired. He has the vision and ambition to take Avomeen to the next level and comes highly recommended from within the industry. David brings to Avomeen his experience with sales integrations, acquisitions, and the launch of new testing opportunities,” said Shri Thanedar, PhD, CEO of Avomeen Analytical Services, in a press release.
Avomeen is a full-service chemical testing laboratory with product testing and formulation development services. The company specializes in deformulation analysis (reverse engineering), product development, stability testing, pharmaceutical research and development, litigation support services, and pharmaceutical product lifecycle support.
Source: Avomeen
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
